甲状腺微小乳头状癌患者偏好由并发症厌恶驱动而非治疗路径
本研究基于10个临床情景,对101名甲状腺癌幸存者使用时间权衡法推导质量调整生命年权重。
要点
- 无并发症时四种治疗路径的QALY权重无显著差异。
- 并发症显著降低QALY权重,主动监测除外。
- 患者偏好由并发症厌恶而非治疗路径驱动。
核心结论
- 无并发症时四种治疗路径的QALY权重相当,患者偏好由并发症厌恶驱动而非治疗路径本身。
研究设计与样本
- 基于10个已发表的甲状腺微小乳头状癌临床情景,对101名甲状腺癌幸存者使用时间权衡法推导QALY权重。
关键数值与推荐
- 无并发症情景中位QALY权重:0.975至0.992。
- 研究效能可检测效应量0.5(即0.04 QALY)的最小重要差异。
临床怎么用
- QALY权重可用于甲状腺微小乳头状癌治疗的价值评估。
- 临床决策应重视患者对并发症的厌恶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Papillary thyroid microcarcinomas carry an excellent prognosis, making patient preferences and cost-effectiveness important determinants of treatment selection. To conduct cost-effectiveness analyses, quality-adjusted life year weights for papillary thyroid microcarcinoma treatments must be derived. Our objective was to estimate the quality-adjusted life year weights of common papillary thyroid microcarcinoma treatment scenarios. METHODS: This study used 10 previously published papillary thyroid microcarcinoma clinical vignettes describing active surveillance, radiofrequency ablation, partial thyroidectomy, and total thyroidectomy, along with potential complications (progression, vocal cord palsy, hypocalcemia). Quality-adjusted life year weights were derived using a time trade-off instrument administered to thyroid cancer survivors. Quality-adjusted life year weights were compared using within-subjects repeated measures analysis of variance and paired Wilcoxon rank-sum tests. The cohort was powered to detect a minimal important difference with an effect size of 0.5 (ie, 0.04 quality-adjusted life year). RESULTS: Data from 101 thyroid cancer survivors were collected. Median quality-adjusted life year weights for uncomplicated treatment scenarios ranged from 0.975 to 0.992 and were not significantly different between treatments (P = .15). Treatment complications resulted in significantly lower quality-adjusted life year weights across all treatment strategies (P < .01) except active surveillance (P = .72). CONCLUSION: Quality-adjusted life year weights were comparable between the uncomplicated versions all 4 treatment pathways, suggesting that patient treatment preferences for papillary thyroid microcarcinoma are driven by aversion to treatment complications, rather than an inclination toward the experience of the treatments themselves. These quality-adjusted life year weights may be readily incorporated into value assessments for papillary thyroid microcarcinoma treatments.
引用
- Kowalski R, Carlisle K, Park AN, et al. Patient preferences in papillary thyroid microcarcinoma management are driven by aversion toward complications rather than treatment pathway. Surgery. 2025. PMID: 41006152. doi:10.1016/j.surg.2025.109694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。